Ellen Sher
Pediatric Endocrinology · Dallas, TXNPI 1548292402
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Pfizer accounts for 79.2% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $4,406, more than ten times the $11 reported in 2019.
Across 101 payments — averaging $91.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$7K
- Ascendis Pharma Endocrinology Inc$446
- AbbVie$223
- Neurocrine Biosciences, Inc.$156
- Jazz Pharmaceuticals Inc.$126
- Amneal Pharmaceuticals LLC$123
- plus $852 from 15 others
Across 20 payments — averaging $693.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$14K
What the payments were for
- Speaking & faculty fees$5,10055%
- Travel & lodging$1,70918%
- Food & beverage$2,43326%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 18 | $7,340 |
| Ascendis Pharma Endocrinology Inc | 21 | $446 |
| AbbVie | 9 | $223 |
| Neurocrine Biosciences, Inc. | 6 | $156 |
| Jazz Pharmaceuticals Inc. | 1 | $126 |
| Amneal Pharmaceuticals LLC | 6 | $123 |
| Endo Pharmaceuticals Inc. | 7 | $118 |
| Endo USA, Inc. | 6 | $109 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Tolmar Pharmaceuticals, Inc. | 4 | $90 |
| Tolmar, Inc. | 4 | $82 |
| Soleno Therapeutics, Inc. | 4 | $77 |
| Novo Nordisk | 3 | $66 |
| Azurity Pharmaceuticals, Inc. | 3 | $64 |
| Rhythm Pharmaceuticals, Inc. | 1 | $31 |
| AstraZeneca | 1 | $31 |
| Ferring Pharmaceuticals Inc. | 2 | $22 |
| Vistapharm, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Eton Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NGENLA$5,100
- GENOTROPIN$1,990
- RYLAZE$126
How this compares
$9,266 in reported general payments places this provider in the 80th percentile of 120 pediatric endocrinology providers in Texas.
Other pediatric endocrinology in Dallas
- Abha ChoudharyDallas$35K
- Nivedita PatniDallas$16K
- Perrin WhiteDallas$11K
- Muniza MogriDallas$9K
- Soumya AdhikariDallas$5K
- Huay Lin LoDallas$893
- Rabab JafriDallas$805
- Ming YangDallas$792
- Katie DolakDallas$570
- Jose Gamez-GodoyEdinburg$207K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.